Literature DB >> 7521355

Enzyme immunoassay with enhanced specificity for detection of antibodies to Chlamydia trachomatis.

J M Ossewaarde1, A de Vries, J A van den Hoek, A M van Loon.   

Abstract

Two different methods for preventing the binding of cross-reacting antibodies to the genus-reactive chlamydial lipopolysaccharide (LPS) were used to improve the specificity of an enzyme immunoassay for the determination of antibodies to Chlamydia trachomatis. Coated elementary bodies were treated with either sodium periodate, to oxidize the antigenic sites of the LPS, or Triton X-100, to extract the LPS. By using these new enzyme immunoassays, the standard enzyme immunoassay, and the whole inclusion fluorescence (WIF) assay, antibodies to C. trachomatis were determined in sera from different groups of patients and controls. Paired serum samples from patients with culture-proven urogenital C. trachomatis infections showed similar responses in all three assays. Paired serum samples from patients with Chlamydia psittaci infections showed similar responses in the WIF assay and the standard enzyme immunoassay, whereas significantly reduced titers were obtained in the enzyme immunoassays with treated antigen, especially in the convalescent-phase serum samples. Serum samples from patients with symptoms suggestive of infection with C. trachomatis, pregnant women, and blood donors were evaluated by all three types of assays. Eighty percent of the significant reductions in immunoglobulin G (IgG), IgA, and IgM titers were observed in sera with WIF assay titers in the lower classes (IgG, 1: < or = 256; IgA, 1: < or = 32; IgM, 1: < or = 16). From these results we conclude that oxidation of the antigen by sodium periodate is a simple and effective method of producing an enzyme immunoassay with enhanced specificity that could be useful for diagnostic purposes and seroepidemiological studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521355      PMCID: PMC264012          DOI: 10.1128/jcm.32.6.1419-1426.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  42 in total

1.  An enzyme immunoassay to detect specific antibodies to protein and lipopolysaccharide antigens of Chlamydia trachomatis.

Authors:  J M Ossewaarde; J W Manten; H J Hooft; A C Hekker
Journal:  J Immunol Methods       Date:  1989-10-24       Impact factor: 2.303

2.  Immunoelectron microscopic localization of chlamydial lipopolysaccharide (LPS) in McCoy cells inoculated with Chlamydia trachomatis.

Authors:  S A Hearn; G L McNabb
Journal:  J Histochem Cytochem       Date:  1991-08       Impact factor: 2.479

3.  Storage conditions of Chlamydia trachomatis antigens.

Authors:  J M Ossewaarde; M Rieffe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

4.  Antigen specific serum antibody response to Chlamydia trachomatis in patients with acute pelvic inflammatory disease.

Authors:  A Miettinen; P K Heinonen; K Teisala; R Punnonen; J Paavonen
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

5.  Incidence of Chlamydia antibody in patient groups, as measured by the ELISA technique.

Authors:  T Ben-Ahmeida; T Smith; D A Hicks; G R Kinghorn; C W Potter
Journal:  Int J STD AIDS       Date:  1990-03       Impact factor: 1.359

6.  Identification of genus-specific epitopes on the outer membrane complexes of Chlamydia trachomatis and Chlamydia psittaci immunotypes 1 and 2.

Authors:  R R Mondesire; I W Maclean; P E Shewen; S E Winston
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

7.  Significance of immunoglobulin A titres in the diagnosis of urogenital chlamydial infections.

Authors:  O Scheel; G Anestad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

8.  Enzyme immunoassay to determine exposure to Chlamydia pneumoniae (strain TWAR).

Authors:  S Ladany; C M Black; C E Farshy; J M Ossewaarde; R C Barnes
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  The development and evaluation of a mu-capture ELISA detecting Chlamydia-specific IgM.

Authors:  T G Wreghitt; V J Robinson; E O Caul; I D Paul; S Gatley
Journal:  Epidemiol Infect       Date:  1988-10       Impact factor: 2.451

10.  Comparison of a single-antigen microimmunofluorescence assay and inclusion fluorescent-antibody assay for detecting chlamydial antibodies and correlation of the results with neutralizing ability.

Authors:  E M Peterson; R Oda; P Tse; C Gastaldi; S C Stone; L M de la Maza
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

View more
  5 in total

1.  Notice of redundancy.

Authors: 
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

2.  Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies.

Authors:  Servaas A Morré; Christian Munk; Kenneth Persson; Susanne Krüger-Kjaer; Rogier van Dijk; Chris J L M Meijer; Adriaan J C van Den Brule
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  Comparison of two panels of monoclonal antibodies for determination of Chlamydia trachomatis serovars.

Authors:  J M Ossewaarde; M Rieffe; A de Vries; R P Derksen-Nawrocki; H J Hooft; G J van Doornum; A M van Loon
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

4.  No association of anti-Chlamydia trachomatis antibodies and severity of cervical neoplasia.

Authors:  N Reesink-Peters; J M Ossewaarde; A G Van Der Zee; W G Quint; M P Burger; A H Adriaanse
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

5.  Low prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae among patients with symptoms of respiratory tract infections in Dutch general practices.

Authors:  A Meijer; C F Dagnelie; J C De Jong; A De Vries; T M Bestebroer; A M Van Loon; A I Bartelds; J M Ossewaarde
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.